Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  asparaginase Erwinia chrysanthemi
Find trials that include:  Any drugs shown
Results 1-5 of 5 for your search:
Start Over
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients with Down Syndrome
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 91 days to 3 years
Trial IDs: AAML1531, NCI-2015-00324, NCT02521493
Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Patients with Refractory or Relapsed Mixed Lineage Leukemia Rearranged Hematologic Malignancies
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: RELMLL, NCI-2015-00602, MLL REC, NCT02419755
Panobinostat, Bortezomib, and Vincristine Sulfate Liposome with Re-induction Therapy in Treating Younger Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: TSALV, NCI-2015-00935, NCT02518750
Fludarabine Phosphate, Cytarabine, and Asparaginase Erwinia Chrysanthemi in Treating Patients with Relapsed or Refractory Hematologic Malignancies
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 to 60
Trial IDs: 2015-0807, NCI-2016-00691, NCT02718755
Asparaginase Erwinia Chrysanthemi in Treating Older Patients with Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: 15-107, NCI-2016-00556, NCT02647190
Start Over